Harvard Psychopharmacology A Master Class 2026

Description

HARVARD • PSYCHOPHARMACOLOGY • 2026

Psychopharmacology: A Master Class 2026

An advanced recorded psychiatry update focused on complex and treatment-resistant psychiatric conditions, modern neurobiology, antidepressant strategies, bipolar disorder, schizophrenia, anxiety, sleep, substance use disorders, neuromodulation, psychedelics, AI and digital therapeutics.

19 VIDEOS 19 VTT SUBTITLES 17 PDFS 6.76 GB LIFETIME ACCESS

2026 Advanced Psychiatry Update

TRD

Resistant DepressionAdvanced antidepressant strategies and difficult-to-treat cases

BIP

Bipolar DisorderRational polypharmacy and bipolar depression

SCZ

SchizophreniaProdrome, first episode, relapse and new treatments

NeuromodulationCurrent and emerging approaches for prescribers

AI & Digital TherapeuticsApps, AI and modern mental-health tools

PTSD

Psychedelics & PTSDMechanisms and emerging treatment approaches

19Recorded Videos

19VTT Subtitles

17PDF Resources

6.76 GBComplete Package

About the Course

Advanced psychopharmacology for complex psychiatric practice.

This two-day Master Class is built for clinicians who manage difficult, treatment-resistant and high-complexity psychiatric conditions.

Psychopharmacology: A Master Class 2026 reviews current neurobiology and practical prescribing strategies for depression, bipolar disorder, schizophrenia, anxiety, sleep disturbance and substance use disorders.

The program also addresses perinatal psychiatry, child and adolescent affective disorders, geriatric psychopharmacology, neuromodulation, psychedelics for PTSD, AI as a therapeutic tool, and laboratory testing intended to predict antidepressant response.

The recorded package includes 19 videos, 19 English VTT subtitle files and 17 PDF learning resources, totaling 6.76 GB, for self-paced review.

Why clinicians choose this program

Treatment-resistant depression and difficult cases

Bipolar disorder and rational polypharmacy

Schizophrenia treatment across illness stages

Perinatal, pediatric and geriatric psychopharmacology

Neuromodulation, psychedelics, AI and digital therapeutics

Practical prescribing updates from expert faculty

Core Learning Areas

From neurobiology to emerging therapies.

The curriculum connects foundational mechanisms with high-level prescribing decisions for complex psychiatric presentations.

MED

Advanced Medication Strategies

Antidepressant development, treatment-resistant depression, bipolar depression, rational polypharmacy, schizophrenia treatment and benzodiazepine considerations.

POP

Special Populations

Perinatal mood and anxiety disorders, child and adolescent affective disorders, geriatric psychopharmacology and neuropsychiatric populations.

EMG

Emerging Treatments

Neuromodulation, psychedelics for PTSD, digital therapeutics, AI-based tools and future treatment strategies.

CLN

Clinical Psychiatry Updates

Neurobiology, sleep in psychiatric disorders, anxiety-spectrum treatment, substance use disorders and predictive laboratory testing.

Course Directors

Meet the official 2026 course leadership.

Harvard lists Matcheri Keshavan, Carl Salzman and Roscoe Brady as the three Course Directors for Psychopharmacology: A Master Class.

Course Director

Matcheri Keshavan, MD

Stanley R. Cobb Professor and Academic Head of Psychiatry

Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center

Harvard Medical School

Course Director

Carl Salzman, MD

Professor of Psychiatry, Harvard Medical School

Beth Israel Deaconess Medical Center

Course Director

Roscoe Brady, MD, PhD

Vice-Chair for Research, Department of Psychiatry

Beth Israel Deaconess Medical Center

Associate Professor, Harvard Medical School

Selected 2026 Faculty

Alan Schatzberg, MD Kristina Deligiannidis, MD Melissa DelBello, MD, MS Alejandro Dan Mendoza, MD Stephen Stahl, MD, PhD John Winkelman, MD, PhD Tony Cunningham, PhD John Torous, MD, MBI Ryan Henner, MD Kevin Hill, MD Pooja Sarkar, MD Charles Nemeroff, MD, PhD

2-Day Curriculum

Two focused days of advanced psychopharmacology and emerging psychiatric treatment.

A concise overview based on Harvard’s official March 2026 schedule.

Day 1

Neurobiology, Mood Disorders, Special Populations & Neuromodulation

Neurobiology for the practicing clinician
Antidepressant development for refractory depression
Bipolar disorder: polypharmacy and bipolar depression
Perinatal mood and anxiety disorders
Child and adolescent affective disorders
Current and emerging neuromodulation approaches
Geriatric psychopharmacology and neuropsychiatry
Difficult-to-treat depression
Expert panel discussions

Day 2

Schizophrenia, Sleep, AI, Psychedelics, Addiction & Anxiety

Schizophrenia: prodrome, first episode, relapse and new treatments
Sleep neurobiology in psychiatric disorders
Apps and AI as therapeutics
Psychedelics and potential treatment for PTSD
Substance use disorder treatment
Anxiety mechanisms and spectrum-disorder treatment
New benzodiazepine data
Laboratory testing to predict antidepressant response
Closing expert panel and clinical questions

Who should take this course?

Designed for clinicians who prescribe, manage or study psychiatric treatment across complex patient populations.

Psychiatrists Psychiatric NPs Primary Care Physicians Physician Assistants Psychologists Residents Fellows Clinical Researchers Mental Health Clinicians Prescribing Professionals

Course Package

Recorded educational access organized for flexible, self-paced review.

Recorded Videos

Complete 2026 psychopharmacology sessions for on-demand review.

VTT Subtitles

English subtitle files supporting easier lecture review.

PDF Resources

Downloadable presentation materials for reference and study.

6.76 GB

Complete Package

Full recorded course package with lifetime access after purchase.

Frequently Asked Questions

Before you download.

Clear answers to common buyer questions.

Is this a live course?

No. This product contains recorded, on-demand educational materials for independent study.

What is included in the course package?

The package includes 19 recorded videos, 19 VTT subtitle files and 17 PDF learning resources, totaling 6.76 GB.

Does the course cover treatment-resistant depression?

Yes. Treatment-resistant and difficult-to-treat depression are major areas of the 2026 program.

Are AI and emerging therapies included?

Yes. The curriculum includes AI and digital therapeutics, neuromodulation, psychedelics for PTSD and emerging treatment strategies.

Does the course include special-population psychopharmacology?

Yes. Perinatal, child and adolescent, and geriatric psychiatric treatment are all included.

How will I receive access after purchase?

Access instructions are provided after your order is completed so you can begin reviewing the available course materials right away.

Does course access expire?

No. Lifetime access is included with the purchased recorded course materials.

Does this recorded package include CME/CE credit or a certificate?

No. CME/CE credit and an official certificate are not included with this recorded course package.

Important: This product provides recorded, on-demand educational materials and is not registration for the original Harvard live event. No CME/CE credit or official certificate is included with this recorded package.

19 RECORDED VIDEOS 19 VTT SUBTITLES 17 PDF RESOURCES LIFETIME ACCESS

PSYCHOPHARMACOLOGY • COMPLEX PSYCHIATRY • 2026

Build a stronger framework for complex psychiatric prescribing.

Review advanced antidepressant strategies, bipolar disorder, schizophrenia, anxiety, sleep, substance use disorders, special populations, neuromodulation, psychedelics and AI — at your own pace.

DOWNLOAD COURSE NOW 19 VIDEOS • 19 VTT SUBTITLES • 17 PDFS • 6.76 GB • LIFETIME ACCESS

Reviews

There are no reviews yet.

Be the first to review “Harvard Psychopharmacology A Master Class 2026”

You must be logged in to post a review.